Comparison of the effect of gonadotropin-releasing hormone agonist and dopamine receptor agonist on uterine myoma growth. Histologic, sonographic, and intra-operative changes

Saudi Medical Journal

Volumn 30, Issue 8, 2009, Pages 1024-1033

  Sayyah Melli, Manizheh ^a   Tehrani Gadim, Sepideh ^a   Dastranj Tabrizi, Ali ^a   Gatrehsamani, Fatemeh ^a   Morteza, Ghojazadeh ^a   Ouladesahemadarek, Elaheh ^a   Farzadi, Laya ^a   Kazemi Shishvan, Maryamalsadat ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; DIPHERELINE; GONADORELIN AGONIST; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MITOSIS INDEX; PELVIS PAIN SYNDROME; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TUMOR GROWTH; UTERUS MYOMA;

ADULT; ANTINEOPLASTIC AGENTS; DOPAMINE AGONISTS; ERGOLINES; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LEIOMYOMA; MIDDLE AGED; TREATMENT OUTCOME; UTERINE NEOPLASMS;

EID: 70349495508     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Okolo S. Incidence, aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obstet Gynaecol 2008; 22: 571-588.
2. Viswanathan M, Hartmann K, McKoy N, Stuart G, Rankins N, Thieda P, et al. Management of uterine fibroids: An update of the evidence. Evid Rep Technol Assess (Full Rep) 2007; 154: 1-122.
3. Ohara N. Action of progesterone receptor modulators on uterine leiomyomas. Clin Exp Obstet Gynecol 2008; 35: 165-166.
4. Blake RE. Leiomyomata uteri: Hormonal and molecular determinants of growth. J Natl Med Assoc 2007; 99: 1170-1184.
5. Yu L, Saile K, Swartz CD, He H, Zheng X, Kissling GE, et al. Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas. Mol Med 2008; 14: 264-275.
6. Pan Q, Luo X, Chegini N. Genomic and proteomic profiling I: Leiomyomas in African Americans and Caucasians. Reprod Biol Endocrinol 2007; 5: 34.
7. Zhao Y, Zhang W, Wang S. The expression of estrogen receptor isoforms alpha, beta and insulin-like growth factor-I in uterine leiomyoma. Gynecol Endocrinol 2008; 24: 549-554.
8. Wei T, Geiser AG, Qian HR, Su C, Helvering LM, Kulkarini NH, et al. DNA microarray data integration by ortholog gene analysis reveals potential molecular mechanisms of estrogen-dependent growth of human uterine fibroids. BMC Womens Health 2007; 7: 5.
9. Rein MS. Advances in uterine leiomyoma research: The progesterone hypothesis. Environ Health Perspect 2000; 108 (Suppl 5): S791-S793.
10. Wolanska M, Bankowska-Guszczyn E, Jaworski S. [Fibroblast growth factor gene expression in uterine leiomyomas] Ginekol Pol 2008; 79: 555-559. Polish.
11. Wise LA, Palmer JR, Harlow BL, Spiegelman D, Stewart EA, Adams-Campbell LL,et al. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: A prospective study. Am J Epidemiol 2004; 159: 113-123.
12. Li S, McLachlan JA. Estrogen-associated genes in uterine leiomyoma. Ann N Y Acad Sci 2001; 948: 112-120.
13. Björnström L, Sjöberg M. Mechanisms of estrogen receptor signaling: Convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 2005; 19: 833-842.
14. Yamamoto T, Urabe M, Naitoh K, Kitawaki J, Honjo H, Okada H. Estrone sulfatase activity in human uterine leiomyoma. Gynecol Oncol 1990; 37: 315-318.
15. Wilson EA, Yang F, Rees ED. Estradiol and progesterone binding in uterine leiomyomata and in normal uterine tissues. Obstet Gynecol 1980; 55: 20-24.
16. Syssoev KA, Kulagina NV, Chukhlovin AB, Morozova EB, Totolian AA. Expression of mRNA for chemokines and chemokine receptors in tissues of the myometrium and uterine leiomyoma. Bull Exp Biol Med 2008; 145: 84-89.
17. Di X, Yu L, Moore AB, Castro L, Zheng X, Hermon T, et al. A low concentration of genistein induces estrogen receptor-alpha and insulin-like growth factor-I receptor interactions and proliferation in uterine leiomyoma cells. Hum Reprod 2008; 23: 1873-1883.
18. Ylikorkala O, Kauppila A, Rajala T. Pituitary gonadotrophins and prolactin in patients with endometrial cancer, fibroids or ovarian tumours. Br J Obstet Gynaecol 1979; 86: 901-904.
19. Spellacy WN, Le Maire WJ, Buhi WC, Birk SA, Bradley BA. Plasma growth hormone and estradiol levels in women with uterine myomas. Obstet Gynecol 1972; 40: 829-834.
20. Augusciak-Duma A, Sieron AL. [Molecular characteristics of leiomyoma uteri based on selected compounds of the extracellular matrisc] Postepy Hig Med Dosw (Online) 2008; 62: 148-165. Polish.
21. Lumsden MA, West CP, Bramley T, Rumgay L, Baird DT. The binding of epidermal growth factor to the human uterus and leiomyomata in women rendered hypo-oestrogenic by continuous administration of an LHRH agonist. Br J Obstet Gynaecol 1988; 95: 1299-1304.
22. Di Lieto A, De Falco M, Staibano S, Iannotti F, Scaramellino M, Salvatore G, et al. Effects of gonadotropin-releasing hormone agonists on uterine volume and vasculature and on the immunohistochemical expression of basic fibroblast growth factor (bFGF) in uterine leiomyomas. Int J Gynecol Pathol 2003; 22: 353-358.
23. Luo X, Pan Q, Liu L, Chegini N. Genomic and proteomic profiling II: comparative assessment of gene expression profiles i n leiomyomas, keloids, and surgically-induced scars. Reprod Biol Endocrinol 2007; 5: 35.
24. Hodge JC, Quade BJ, Rubin MA, Stewart EA, Dal Cin P, Morton CC. Molecular and cytogenetic characterization of plexiform leiomyomata provide further evidence for genetic heterogeneity underlying uterine fibroids. Am J Pathol 2008; 172: 1403-1410.
25. Hudson SB, Stewart EA. Magnetic resonance-guided focused ultrasound surgery. Clin Obstet Gynecol 2008; 51: 159-166.
26. Lefebvre G, Vilos G, Allaire C, Jeffrey J, Arneja J, Birch C, et al. The management of uterine leiomyomas. J Obstet Gynaecol Can 2003; 25: 396-418.
27. Goldzieher JW, Maqueo M, Ricaud L, Aguilar JA, Canales E. Induction of degenerative changes in uterine myomas by high-dosage progestin therapy. Am J Obstet Gynecol 1966; 96: 1078-1087.
28. Deligdisch L, Hirschmann S, Altchek A. Pathologic changes in gonadotropin releasing hormone agonist analogue treated uterine leiomyomata. Fertil Steril 1997; 67: 837-841.
29. Nakayama M, Mitsuhashi T, Shimizu Y, Ishihara O, Shimizu M. Pathological evaluation of uterine leiomyomas treated with gonadotropin-releasing hormone agonist (GnRH-a) therapy: Role of mast cells and a possible mechanism of GnRH-a resistance in leiomyomas. Pathol Int 2008; 58: 268-274.
30. Weeks AD, Duffy SR, Walker JJ. Uterine ultrasonographic changes with gonadotropin-releasing hormone agonists. Am J Obstet Gynecol 1999; 180: 8-13.
31. Ito F, Kawamura N, Ichimura T, Tsujimura A, Ishiko O, Ogita S. Ultrastructural comparison of uterine leiomyoma cells from the same myoma nodule before and after gonadotropin-releasing hormone agonist treatment. Fertil Steril 2001; 75: 125-130.
32. Mizutani T, Sugihara A, Nakamuro K, Terada N. Suppression of cell proliferation and induction of apoptosis in uterine leiomyoma by gonadotropin-releasing hormone agonist (leuprolide acetate). J Clin Endocrinol Metab 1998; 83: 1253-1255.
33. Campo S, Campo V, Gambadauro P. Short-term and long-term results of resectoscopic myomectomy with and without pretreatment with GnRH analogs in premenopausal women. Acta Obstet Gynecol Scand 2005; 84: 756-760.
34. Friedman AJ, Juneau-Norcross M, Rein MS. Adverse effects of leuprolide acetate depot treatment. Fertil Steril 1993; 59: 448-450.
35. Carr BR, Marshburn PB, Weatherall PT, Bradshaw KD, Breslau NA, Byrd W, et al. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: A prospective, randomized, double blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab 1993; 76: 1217-1223.
36. Murphy AA, Kettel LM, Morales AJ, Roberts VJ, Yen SS. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab 1993; 76: 513-517.
37. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin (PRL) and its receptor: Actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 1998; 19: 225-268.
38. Nowak RA, Mora S, Diehl T, Rhoades AR, Stewart EA. Prolactin is an autocrine or paracrine growth factor for human myometrial and leiomyoma cells. Gynecol Obstet Invest 1999; 48: 127-132.
39. Melli MS, Farzadi L, Madarek EO. Comparison of the effect of gonadotropin-releasing hormone analog (Diphereline) and Cabergoline (Dostinex) treatment on uterine myoma regression. Saudi Med J 2007; 28: 445-450.
40. Day Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003; 188: 100-107.
41. Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol 1990; 94: 435-438.
42. Ryan GL, Syrop CH, Van Voorhis BJ. Role, epidemiology, and natural history of benign uterine mass lesions. Clin Obstet Gynecol 2005; 48: 312-324.
43. Practice Committee of the American Society for Reproductive Medicine. Myomas and reproductive function. Fertil Steril 2004; 82 (Suppl 1): S111-S116.
44. Donnez J, Jadoul P. What are the implications of myomas on fertility? A need for a debate? Hum Reprod 2002; 17: 1424-1430.
45. Wallach EE, Vlahos NF. Uterine myomas: An overview of development, clinical features, and management. Obstet Gynecol 2004; 104: 393-406.
46. ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. Surgical alternatives to hysterectomy in the management of leiomyomas. Number 16, May 2000 (replaces educational bulletin number 192, May 1994). Int J Gynaecol Obstet 2001; 73: 285-293
47. Stewart EA. Uterine Fibroids: The Complete Guide. Baltimore (MD): Johns Hopkins Press Health Book; 2007.
48. Flynn M, Jamison M, Datta S, Myers E. Health care resource use for uterine fibroid tumors in the United States. Am J Obstet Gynecol 2006; 195: 955-964.
49. Stewart EA, Rabinovici J, Tempany CM, Inbar Y, Regan L, Gostout B, et al. Clinical outcomes of focused ultrasound surgery for the treatment of uterine fibroids. Fertil Steril 2006; 85: 22-29.
50. Hesley GK, Felmlee JP, Gebhart JB, Dunagan KT, Gorny KR, Kesler JB, et al. Noninvasive treatment of uterine fibroids: Early Mayo Clinic experience with magnetic resonance imaging-guided focused ultrasound. Mayo Clin Proc 2006; 81: 936-942.
51. Edwards RD, Moss JG, Lumsden MA, Wu O, Murray LS, Twaddle S, et al. Uterine-artery embolization versus surgery for symptomatic uterine fibroids. N Engl J Med 2007; 356: 360-370.
52. Reinsch RC, Murphy AA, Morales AJ, Yen SS. The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: A prospective, randomized study. Am J Obstet Gynecol 1994; 170: 1623-1627.
53. Exacoustos C, Romanini ME, Amadio A, Amoroso C, Szabolcs B, Zupi E, et al. Can gray-scale and color Doppler sonography differentiate between uterine leiomyosarcoma and leiomyoma? J Clin Ultrasound 2007; 35: 449-457.
54. Mayer A, Höckel M, Wree A, Leo C, Horn LC, Vaupel P. Lack of hypoxic response in uterine leiomyomas despite severe tissue hypoxia. Cancer Res 2008; 68: 4719-4726.
55. Cheng YM, Chou CY, Huang SC, Lin HC. Oestrogen deficiency causes DNA damage in uterine leiomyoma cells: A possible mechanism for shrinkage of fibroids by GnRH agonists. BJOG 2001; 108: 95-102.
56. Friedman AJ, Lobel SM, Rein MS, Barbieri RL. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: The estrogen threshold hypothesis. Am J Obstet Gynecol 1990; 163: 1114-1119.
57. Friedman AJ, Barbieri RL, Doubilet PM, Fine C, Schiff I. A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri. Fertil Steril 1988; 49: 404-409.
58. Lethaby A, Vollenhoven B, Sowter M. Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: A systematic review. BJOG 2002; 109: 1097-1108.
59. Stovall TG, Muneyyirci-Delale O, Summitt RL Jr, Scialli AR. GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: A randomized controlled trial. Leuprolide Acetate Study Group. Obstet Gynecol 1995; 86: 65-71.
60. Stovall TG, Ling FW, Henry LC, Woodruff MR. A randomized trial evaluating leuprolide acetate before hysterectomy as treatment for leiomyomas. Am J Obstet Gynecol 1991; 164: 1420-1423.
61. Vercellini P, Crosignani PG, Mangioni C, Imparato E, Ferrari A, De Giorgi O. Treatment with a gonadotrophin releasing hormone agonist before hysterectomy for leiomyomas: Results of a multicentre, randomised controlled trial. Br J Obstet Gynaecol 1998; 105: 1148-1154.
62. Imai A, Sugiyama M, Furui T, Takahashi S, Tamaya T. Gonadotrophin-releasing hormones agonist therapy increases peritoneal fibrinolytic activity and prevents adhesion formation after myomectomy. J Obstet Gynaecol 2003; 23: 660-663.
63. McClean G, McCluggage WG. Unusual morphologic features of uterine leiomyomas treated with gonadotropin-releasing hormone agonists: Massive lymphoid infiltration and vasculitis. Int J Surg Pathol 2003; 11: 339-344.
64. Resta L, Sanguedolce F, Orsini G, Laricchia L, Piscitelli D, Fiore MG. Morphometric and histological evaluation of uterine leiomyomas treated with GnRH agonists or progestational agents. Pathologica 2004; 96: 35-41.
65. Kawamura N, Ito F, Ichimura T, Shibata S, Umesaki N, Ogita S. Correlation between shrinkage of uterine leiomyoma treated with buserelin acetate and histopathologic findings of biopsy specimen before treatment. Fertil Steril 1997; 68: 632-636.
66. Di Lieto A, De Falco M, Pollio F, Mansueto G, Salvatore G, Somma P, et al. Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas. J Soc Gynecol Investig 2005; 12: 123-128.
67. Flierman PA, Oberyé JJ, van der Hulst VP, de Blok S. Rapid reduction of leiomyoma volume during treatment with the GnRH antagonist ganirelix. BJOG 2005; 112: 638-642.
68. Moghissi KS. Hormonal therapy before surgical treatment for uterine leiomyomas. Surg Gynecol Obstet 1991; 172: 497-502.
69. Deligdisch L, Hirschmann S, Altchek A. Pathologic changes in gonadotropin releasing hormone agonist analogue treated uterine leiomyomata. Fertil Steril 1997; 67: 837-841.
70. Wang Y, Matsuo H, Kurachi O, Maruo T. Down-regulation of proliferation and up-regulation of apoptosis by gonadotropin-releasing hormone agonist in cultured uterine leiomyoma cells. Eur J Endocrinol 2002; 146: 447-456.
71. Dawood MY, Lewis V, Ramos J. Cortical and trabecular bone mineral content in women with endometriosis: Effect of gonadotropin-releasing hormone agonist and danazol. Fertil Steril 1989; 52: 21-26.
72. Matta WH, Stabile I, Shaw RW, Campbell S. Doppler assessment of uterine blood flow changes in patients with fibroids receiving the gonadotropin-releasing hormone agonist Buserelin. Fertil Steril 1988; 49: 1083-1085.
73. Rein MS, Barbieri RL, Welch W, Gleason RE, Caulfield JP, Friedman AJ. The concentrations of collagen-associated amino acids are higher in GnRH agonist-treated uterine myomas. Obstet Gynecol 1993; 82: 901-905.
74. Lefebvre G, Vilos G, Allaire C, Jeffrey J, Arneja J, Birch C, et al. The management of uterine leiomyomas. J Obstet Gynaecol Can 2003; 25: 396-418.